Cancer News and Research RSS Feed - Cancer News and Research Twitter

Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.

Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Treatment plans may include surgery, radiation and/or chemotherapy.
UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers. [More]
Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. [More]
Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. [More]
Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02. [More]
RNA-binding protein ROQUIN regulates response to DNA damage

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules. [More]
Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. [More]
Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. [More]
BUSM researchers find new way to detect and treat basal-like breast cancer

BUSM researchers find new way to detect and treat basal-like breast cancer

A new way to detect - and perhaps treat - one of the deadliest types of breast cancer has been found. Led by researchers at Boston University School of Medicine (BUSM), the study appears online in Breast Cancer Research. [More]
Researchers quantify growth and composition of breast tumours in living animal

Researchers quantify growth and composition of breast tumours in living animal

The ability to visualize and characterize the composition of a tumour in detail during its development can provide valuable insights in order to target appropriate therapeutics. [More]
High levels of specific proteins in urine can accurately detect early-stage pancreatic cancer

High levels of specific proteins in urine can accurately detect early-stage pancreatic cancer

A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, UK researchers have found. [More]
New study on photoaging could minimize risk of skin cancer

New study on photoaging could minimize risk of skin cancer

While all human organs undergo normal, chronological aging, human skin undergoes an additional type of aging because of its direct contact with the environment. [More]
Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Atomic level images reveal how neuropeptide hormone neurotensin may activate its receptors

Many hormones and neurotransmitters work by binding to receptors on a cell's exterior surface. This activates receptors causing them to twist, turn and spark chemical reactions inside cells. [More]
Lancet Series examines enduring radiological, psychological impact of nuclear disasters

Lancet Series examines enduring radiological, psychological impact of nuclear disasters

On the 70th anniversary of the atomic bombs in Hiroshima and Nagasaki, a three-part Series published in The Lancet looks at the enduring radiological and psychological impact of nuclear disasters, including the most recent accident at the Fukushima Daiichi nuclear power plant in Japan in 2011. [More]

Childhood cancer cells produce molecule that affects body's immune system to fight disease

Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body's immune cells, leaving them too physically drained to fight the disease, according to new research published in the journal Cancer Research today (Saturday). [More]
BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks. [More]
FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours. [More]
Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer. [More]

Researchers gain new insight into the stages of breast cancer growth

The ability to visualize and characterize the composition of a tumour in detail during its development can provide valuable insights in order to target appropriate therapeutics. The polymer chemist Prof. Dr. Prasad Shastri and the pharmacist Jon Christensen, in collaboration with the biomedical researcher Dr. Daniel Vonwil, from the University of Freiburg have visualized and quantified the growth and composition of breast tumours over time in a living animal. [More]
Taiwanese scientists propose advanced solution that can be applied to thermal cancer therapy

Taiwanese scientists propose advanced solution that can be applied to thermal cancer therapy

Precise targeting biological molecules, such as cancer cells, for treatment is a challenge, due to their sheer size. Now, Taiwanese scientists have proposed an advanced solution, based on a novel combination of previously used techniques, which can potentially be applied to thermal cancer therapy. [More]
BGI to hold 10th International Conference on Genomics in October

BGI to hold 10th International Conference on Genomics in October

The 10th International Conference on Genomics (ICG-10) will be held by BGI from October 22-25, 2015, in Shenzhen, China. [More]
Advertisement
Advertisement